Since there is more recent evidence showing that activating WNT/β-catenin signaling is associated with innate resistance to immune checkpoint inhibitors, further research is needed in terms of CTNNB1 mutation and subsequent activation of WNT/β-catenin signaling in association with immunotherapy resistance in HCC [23, 43]. This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.